Zumutor’s ADCC improvement platform is ready to deploy
Zumutor has developed multiple expression platforms which lead to improvement of antibody dependent cellular cytotoxicity of therapeutic antibodies. The ADCC Improvement Platform and methods of development are unique and we have filed patent applications to secure global IP rights. All R &D activities related to our ADCC Improvement Platform are carried out in our facilities in India